- Home
- CATX vs LIEN Comparison
CATX vs LIEN Comparison
Compare CATX & LIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- LIEN
- Stock Information
- Founded
- CATX 1983
- LIEN 2021
- Country
- CATX United States
- LIEN United States
- Employees
- CATX N/A
- LIEN N/A
- Industry
- CATX Medical/Dental Instruments
- LIEN
- Sector
- CATX Health Care
- LIEN
- Exchange
- CATX Nasdaq
- LIEN NYSE
- Market Cap
- CATX 239.0M
- LIEN 234.6M
- IPO Year
- CATX N/A
- LIEN 2022
- Fundamental
- Price
- CATX $3.97
- LIEN $10.75
- Analyst Decision
- CATX Strong Buy
- LIEN Buy
- Analyst Count
- CATX 11
- LIEN 2
- Target Price
- CATX $12.90
- LIEN N/A
- AVG Volume (30 Days)
- CATX 1.3M
- LIEN 61.1K
- Earning Date
- CATX 08-11-2025
- LIEN 08-07-2025
- Dividend Yield
- CATX N/A
- LIEN 12.53%
- EPS Growth
- CATX N/A
- LIEN 30.25
- EPS
- CATX N/A
- LIEN 1.15
- Revenue
- CATX $1,471,000.00
- LIEN $30,828,508.00
- Revenue This Year
- CATX N/A
- LIEN $154.46
- Revenue Next Year
- CATX N/A
- LIEN $10.64
- P/E Ratio
- CATX N/A
- LIEN $9.29
- Revenue Growth
- CATX N/A
- LIEN 151.96
- 52 Week Low
- CATX $1.60
- LIEN $9.70
- 52 Week High
- CATX $16.55
- LIEN $13.38
- Technical
- Relative Strength Index (RSI)
- CATX 61.19
- LIEN N/A
- Support Level
- CATX $3.33
- LIEN N/A
- Resistance Level
- CATX $3.69
- LIEN N/A
- Average True Range (ATR)
- CATX 0.38
- LIEN 0.00
- MACD
- CATX 0.01
- LIEN 0.00
- Stochastic Oscillator
- CATX 64.23
- LIEN 0.00
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.